BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 28245132)

  • 21. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation.
    Yoder NC; Bai C; Tavares D; Widdison WC; Whiteman KR; Wilhelm A; Wilhelm SD; McShea MA; Maloney EK; Ab O; Wang L; Jin S; Erickson HK; Keating TA; Lambert JM
    Mol Pharm; 2019 Sep; 16(9):3926-3937. PubMed ID: 31287952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-Specific Antibody Drug Conjugates Using Streamlined Expressed Protein Ligation.
    Frutos S; Hernández JL; Otero A; Calvis C; Adan J; Mitjans F; Vila-Perelló M
    Bioconjug Chem; 2018 Nov; 29(11):3503-3508. PubMed ID: 30346741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
    Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
    Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
    [No Abstract]   [Full Text] [Related]  

  • 27. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs.
    Zheng K; Chen Y; Wang J; Zheng L; Hutchinson M; Persson J; Ji J
    J Pharm Sci; 2019 Jan; 108(1):133-141. PubMed ID: 30458165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates: current status and future directions.
    Perez HL; Cardarelli PM; Deshpande S; Gangwar S; Schroeder GM; Vite GD; Borzilleri RM
    Drug Discov Today; 2014 Jul; 19(7):869-81. PubMed ID: 24239727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
    Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
    ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
    Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
    Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.
    Axup JY; Bajjuri KM; Ritland M; Hutchins BM; Kim CH; Kazane SA; Halder R; Forsyth JS; Santidrian AF; Stafin K; Lu Y; Tran H; Seller AJ; Biroc SL; Szydlik A; Pinkstaff JK; Tian F; Sinha SC; Felding-Habermann B; Smider VV; Schultz PG
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16101-6. PubMed ID: 22988081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
    Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
    J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
    Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
    J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-specific antibody-drug conjugation through glycoengineering.
    Zhou Q; Stefano JE; Manning C; Kyazike J; Chen B; Gianolio DA; Park A; Busch M; Bird J; Zheng X; Simonds-Mannes H; Kim J; Gregory RC; Miller RJ; Brondyk WH; Dhal PK; Pan CQ
    Bioconjug Chem; 2014 Mar; 25(3):510-20. PubMed ID: 24533768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
    Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
    Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.
    Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA
    Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.